INCY News and Press, Incyte Corporation From 10/16/23

Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. "We look forward to sharing data from our oncology portfolio with the ...

2023-10-13 11:28:03 ET Biopharmaceutical Incyte ( NASDAQ: INCY ) Friday announced that the phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream, Opzelura, in children between ages 2 - 12 with atopic dermatitis met its primary endpoint. Data from the TRu...

- In the TRuE-AD3 trial, children (age ≥2 to <12 years old) with atopic dermatitis (AD) treated with ruxolitinib cream achieved significant efficacy, as defined by the Investigator’s Global Assessment-treatment success (IGA-TS), following eight weeks of treatment - In a...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA...

PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness...

2023-10-11 13:35:35 ET More on Syndax Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Biggest stock movers today: Arch Resources, Coinbase Global and more Syndax Pharma falls aft...

- Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years - Results were presented in a late-breaking news session at the European Academy of Dermatolo...

Incyte (Nasdaq:INCY) announced today its partnership with actress, singer and songwriter Mandy Moore on Moments of Clarity , an educational initiative highlighting the authentic stories of people living with mild to moderate atopic dermatitis (AD) and their journey to finding relief from ...

- Longer-term use of povorcitinib resulted in further improvement in total body and facial repigmentation - Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 Incyte (Nasdaq:INCY) today announced new...

MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, t...